Transcode Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Transcode Therapeutics Current Ratio Growth & History (RNAZ)
Transcode Therapeutics's current ratio was 6.29 for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 6.29 | 3.73 | +145.85% |
| 2024 | 2024-12-31 | 2.56 | 1.28 | +100.49% |
| 2023 | 2023-12-31 | 1.28 | −0.42 | −24.81% |
| 2022 | 2022-12-31 | 1.70 | −7.27 | −81.08% |
| 2021 | 2021-12-31 | 8.97 | 6.92 | +336.93% |
| 2020 | 2020-12-31 | 2.05 | — | — |
Transcode Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.97 | −3.29 | −62.57% |
| Q1 2026 | 2026-03-31 | 3.11 | −2.08 | −40.09% |
| Q4 2025 | 2025-12-31 | 6.29 | 3.73 | +145.85% |
| Q3 2025 | 2025-09-30 | 1.60 | 0.02 | +1.21% |
| Q2 2025 | 2025-06-30 | 5.27 | 4.01 | +320.49% |
| Q1 2025 | 2025-03-31 | 5.20 | 2.72 | +109.50% |
| Q4 2024 | 2024-12-31 | 2.56 | 1.28 | +100.49% |
| Q3 2024 | 2024-09-30 | 1.58 | −0.09 | −5.53% |
| Q2 2024 | 2024-06-30 | 1.25 | −0.14 | −9.81% |
| Q1 2024 | 2024-03-31 | 2.48 | 1.68 | +211.05% |
| Q4 2023 | 2023-12-31 | 1.28 | −0.42 | −24.81% |
| Q3 2023 | 2023-09-30 | 1.67 | −1.39 | −45.42% |
| Q2 2023 | 2023-06-30 | 1.39 | −6.67 | −82.77% |
| Q1 2023 | 2023-03-31 | 0.80 | −9.28 | −92.08% |
| Q4 2022 | 2022-12-31 | 1.70 | −7.27 | −81.08% |
| Q3 2022 | 2022-09-30 | 3.07 | −8.36 | −73.16% |
| Q2 2022 | 2022-06-30 | 8.06 | 7.71 | +2187.23% |
| Q1 2022 | 2022-03-31 | 10.08 | — | — |
| Q4 2021 | 2021-12-31 | 8.97 | 6.92 | +336.93% |
| Q3 2021 | 2021-09-30 | 11.43 | — | — |
| Q2 2021 | 2021-06-30 | 0.35 | — | — |
| Q4 2020 | 2020-12-31 | 2.05 | — | — |
Transcode Therapeutics current ratio trends
Over the last five fiscal years, Transcode Therapeutics's current ratio increased from 2.05 to 6.29, a change of 4.24. The latest reported quarter, Q2 2026, shows 1.97.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗